Recently, China Resources Pharmaceutical announced that the company's subsidiary China Resources Sanjiu achieved a total operating income of RMB 12.
111 billion (the same below) for the nine months ended September 30, 2022, an increase of 7.
53% over the same period last year; the net profit attributable to shareholders of listed companies was 1.
952 billion yuan, an increase of 11.
17% over the same period last year; Basic earnings per share were $
1.
99.
Out of optimism about its performance growth, Guojin Securities issued a research report on October 11, saying that it gave China Resources 39 a buy rating
.
The reasons for the rating mainly include: 1) the good development of CHC is sustainable, and the performance growth is driven by the efforts of multiple categories; 2) The business structure of the prescription drug sector is optimized, and a recovery rebound is expected in the fourth quarter; 3) Continue to pay attention to the opportunities of industry cooperation and integration of high-quality resources to achieve multi-directional and coordinated development
.
It is understood that before this, Kangyuan Pharmaceutical has also announced the third quarter report of 2022, achieving operating income of 1.
028 billion yuan, a year-on-year increase of 26.
25%; the net profit was 70.
2172 million yuan, a year-on-year increase of 47.
48%; Basic earnings per share were $
0.
12.
Due to the company's outstanding performance, Zheshang Securities also gave Kangyuan Pharmaceutical an overweight rating
in the research report released on October 9.
In fact, when the third quarter is about to end, many listed companies have successively released performance forecasts for the first three quarters, among which Kelun Pharmaceutical disclosed its performance forecast, which is expected to have a net profit of 1.
315 billion yuan to 1.
442 billion yuan in the first three quarters, a year-on-year increase of 55%-70%; Li Pharmaceutical expects its net profit to increase by 52.
07%-59.
67% in the first three quarters, about 200 million yuan to 210 million yuan; CapBio expects the net profit in the first three quarters to increase by 108.
68%-124.
14%, about 13500000 yuan-1450000 yuan.
.
.
Judging from the performance forecasts released by enterprises at that time and the new meso-economic data, the industry generally believes that the prosperity of the pharmaceutical industry is good, and the performance growth of a large number of pharmaceutical companies in the first three quarters will be the main trend of
the industry.
At the same time, these companies with better performance in pharmaceutical companies will also receive more attention
from investors.
However, it should be noted that because the pharmaceutical market and enterprise development are full of changes, there are also corporate performance or unsatisfactory
.
It is understood that InnoCare is expected to have a higher loss during the reporting period, ranging from -544 million yuan to -664 million yuan, a year-on-year decrease of 718.
81% to 855.
31%, which is also a stock
with a large decline in net profit attributable to the first three quarters.
According to the data, InnoCare is an innovative biopharmaceutical enterprise with independent research and development capabilities as the core driving force, focusing on areas with huge unmet clinical needs such as tumors and autoimmune diseases, and developing best-in-class or first-in-class drugs
with breakthrough potential in the global market.
For the reasons for the expected decline in the performance of the first three quarters, InnoCare explained that on the one hand, the company reached a licensing cooperation with Biogen on orelabrutinib in the same period last year, and the technology licensing revenue confirmed was higher; On the other hand, the Company expects a relatively high amount of unrealized exchange losses from January to September 2022, and the relevant forecasts are based on the Company's estimates of exchange rates, and there is a possibility
of certain fluctuations.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
